Virus Inactivation in the 1990s and into the 21st Century

Sofer,Gail;Jeri Ann Boose;Dorothy C. Lister;

Publication

Article

April 15, 2003

BioPharm International

BioPharm International-04-01-2003

Volume16

Issue 4

Virus Inactivation in the 1990s and into the 21st Century

Author(s):

Gail Sofer,Jeri Ann Boose

by Gail Sofer, BioReliance Dorothy C. Lister, and Jeri Ann Boose Smallest of the microorganisms, viruses depend on other cells ? like those used by biopharmaceutical manufacturers ? for reproduction. And viruses and drug products are idiosyncratic: Both the inactivation process and the product strongly influence the successful outcome. In this conclusion to the virus inactivation series, model ivruses are used to represent single- and double-stranded DNA and RNA viruses, to enable you to reach conclusions about effective inactivation methods for a range of viruses.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Virus Inactivation in the 1990s and into the 21st Century

Using Peptide Maps as Identity and Purity Tests for Lot Release Testing of Recombinant Therapeutic Proteins

Getting Ready for Risk-Based GMPs

GMP Issues: Breaking Ground

Guest Editorial: Benchmarking Biotech

Optimized Nutrient Additives for Fed-Batch Cultures

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!